logo
logo
TCRX stock ticker logo

TScan Therapeutics, Inc.

NASDAQ•TCRX
CEO: Dr. Gavin MacBeath Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-07-16
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Contact Information
830 Winter Street, Waltham, MA, 02451, United States
857-399-9500
www.tscan.com
Market Cap
$55.71M
P/E (TTM)
-1.0
24.5
Dividend Yield
--
52W High
$2.57
52W Low
$0.88
52W Range
2%
Rank54Top 78.1%
2.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Deep Research

Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data